Details of Data Requests to Use Johnson and Johnson Data
Request listing updated daily
All Requests
The YODA Project posts proposals once data access has been granted or denied.
Approved Requests
The YODA Project posts approved proposals once data access has been granted.
Withdrawn Requests
The following data requests could not be fulfilled due to patient privacy concerns, data element availability, data security concerns, or lack of research proposal clarity. The YODA Project posts withdrawn/unapproved proposals at the time the decision is made.
Filters list
Search By Protocol Number
Product of Interest
PI Country
PI Affiliation
Year of Data Access
NO. Trials Provided
Results
Project Status
YODA Protocol Number
2022-5104
Product(s) of Interest REMICADE® (Infliximab) SIMPONI® (Golimumab) STELARA® (Ustekinumab)
NO. Trials Provided 6
Product(s) of Interest REMICADE® (Infliximab) SIMPONI® (Golimumab) STELARA® (Ustekinumab)
NO. Trials Provided 6
Publication Available!
Published
Biomarkers for Predicting Long-term Outcomes in Ulcerative Colitis
Principal Investigator
Rirong Chen
The first affiliated hospital of Sun Yet-sen University
Reports and Publications
Fecal lactoferrin early predicts long-term outcomes in ulcerative colitis: A post-hoc analysis of the UNIFI and PURSUIT trials
YODA Protocol Number
2021-4846
Product(s) of Interest ERLEADA® (Apalutamide)
NO. Trials Provided 1
Product(s) of Interest ERLEADA® (Apalutamide)
NO. Trials Provided 1
Publication Available!
Published
External Validation of a Prognostic Model of Overall Survival In Men with Metastatic Castration-Resistant Prostate Cancer
Principal Investigator
Susan Halabi
Duke University
Reports and Publications
J Clin Oncol . 2023
YODA Protocol Number
2021-4822
Product(s) of Interest STELARA® (Ustekinumab)
NO. Trials Provided 2
Product(s) of Interest STELARA® (Ustekinumab)
NO. Trials Provided 2
Publication Available!
Ongoing
Comparative Efficacy of Ustekinumab and Infliximab on One Year Outcomes Among Biologic-nave Induction Responders in Crohn?s Disease
Principal Investigator
Neeraj Narula
Hamilton Health Sciences
Reports and Publications
Inflamm Bowel Dis. 2022
YODA Protocol Number
2021-4779
Product(s) of Interest REMICADE® (Infliximab) STELARA® (Ustekinumab) SIMPONI® (Golimumab)
NO. Trials Provided 6
Product(s) of Interest REMICADE® (Infliximab) STELARA® (Ustekinumab) SIMPONI® (Golimumab)
NO. Trials Provided 6
Publication Available!
Published
Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn?s Disease
Principal Investigator
Neeraj Narula
Hamilton Health Sciences
Reports and Publications
Clin Gastroenterol Hepatol . 2022
YODA Protocol Number
2021-4778
Product(s) of Interest STELARA® (Ustekinumab)
NO. Trials Provided 3
Product(s) of Interest STELARA® (Ustekinumab)
NO. Trials Provided 3
Publication Availible!
Published
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn?s Disease
Principal Investigator
Neeraj Narula
Hamilton Health Sciences
Reports and Publications
AJG 2022
YODA Protocol Number
2021-4757
Product(s) of Interest REMICADE® (Infliximab)
NO. Trials Provided 2
Product(s) of Interest REMICADE® (Infliximab)
NO. Trials Provided 2
Publication Available!
Published
A Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative Colitis.
Principal Investigator
Neeraj Narula
Hamilton Health Sciences
Reports and Publications
Digestive Diseases and Sciences
YODA Protocol Number
2021-4684
Product(s) of Interest STELARA® (Ustekinumab)
NO. Trials Provided 3
Product(s) of Interest STELARA® (Ustekinumab)
NO. Trials Provided 3
Publications Available! (see more below)
Published
Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn?s Disease
Principal Investigator
Neeraj Narula
Hamilton Health Sciences
Reports and Publications
Aliment Pharmacol Ther. 2022
| J Chron’s Colitis. 2022
YODA Protocol Number
2021-4637
Product(s) of Interest SPRAVATO® (Esketamine)
NO. Trials Provided 3
Product(s) of Interest SPRAVATO® (Esketamine)
NO. Trials Provided 3
Publication Available!
Published
Data-sharing and re-analysis for main studies assessed by the European Medicines Agency – a cross-sectional study on EPARs
Principal Investigator
Florian Naudet
University of Rennes 1
Reports and Publications
BMC 2023
YODA Protocol Number
2021-4602
Product(s) of Interest STELARA® (Ustekinumab) REMICADE® (Infliximab)
NO. Trials Provided 4
Product(s) of Interest STELARA® (Ustekinumab) REMICADE® (Infliximab)
NO. Trials Provided 4
Publication Available!
Published
Modified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohn?s Disease
Principal Investigator
Neeraj Narula
Hamilton Health Sciences
Reports and Publications
Journal of Chron’s & Colitis
YODA Protocol Number
2021-4599
Product(s) of Interest DARZALEX® (Daratumumab)
NO. Trials Provided 6
Product(s) of Interest DARZALEX® (Daratumumab)
NO. Trials Provided 6
Publication Available!
Published
Outcomes with Early versus Late Response to Daratumumab in Patients with Refractory/Relapsed or Newly Diagnosed Multiple Myeloma
Principal Investigator
Jiasheng Wang
MetroHealth Medical Center
Reports and Publications
Leuk Lymphoma 2022